MedTrace Logo

Risk of Hematoma After Ketorolac Use in Reduction Mammoplasty.

NCT03280043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2017-09-12

No results posted yet for this study

Summary

The investigators hope to answer the question, "does ketorolac increase the risk of hematoma after reduction mammoplasty?" using a case-control study. All patients who developed a hematoma post reduction mammoplasty (cases) at our institution, and match these with women who had an uncomplicated reduction mammoplasty (controls), and then compare frequency of ketorolac exposure between these two groups as the primary outcome. If ketorolac increases the risk of hematoma, one should expect cases to have been exposed to ketorolac more frequently than controls. Based on previously existing literature, the investigators hypothesize that cases and controls will not differ in their ketorolac exposure, that is, ketorolac does not increase the risk of hematoma.

Conditions

  • Breast Reduction
  • Reduction Mammoplasty
  • Hematoma
  • Hemorrhage

Interventions

PROCEDURE

Hematoma

Hematoma requiring return to operating room.

Sponsors & Collaborators

Principal Investigators

  • Achilleas Thoma, MD, MSc, BSc · McMaster University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2017-05-20
Completion
2017-08-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280043 on ClinicalTrials.gov